TiumBio Co., Ltd. (KOSDAQ: 321550)
South Korea
· Delayed Price · Currency is KRW 4,400.00
-25.00 (-0.56%)
Dec 19, 2024, 9:00 AM KST
TiumBio Company Description
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases.
The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP.
It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates.
TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea.
TiumBio Co., Ltd.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 42 |
| CEO | Huntaek Kim |
Contact Details
Address: 49, Daewangpangyo-ro 644beon-gil Seongnam-si, 13493 South Korea | |
| Phone | 82 3 1600 1500 |
| Website | tiumbio.com |
Stock Details
| Ticker Symbol | 321550 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Huntaek Kim | Chief Executive Officer |
| Hyunsil Koh | Chief Financial Officer |